Apontis Pharma AG (APPH) - Net Assets
Based on the latest financial reports, Apontis Pharma AG (APPH) has net assets worth €31.62 Million EUR (≈ $36.97 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€43.99 Million ≈ $51.43 Million USD) and total liabilities (€12.37 Million ≈ $14.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check APPH financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €31.62 Million |
| % of Total Assets | 71.89% |
| Annual Growth Rate | 28.05% |
| 5-Year Change | 796.89% |
| 10-Year Change | N/A |
| Growth Volatility | 407.84 |
Apontis Pharma AG - Net Assets Trend (2018–2024)
This chart illustrates how Apontis Pharma AG's net assets have evolved over time, based on quarterly financial data. Also explore how large is Apontis Pharma AG's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Apontis Pharma AG (2018–2024)
The table below shows the annual net assets of Apontis Pharma AG from 2018 to 2024. For live valuation and market cap data, see Apontis Pharma AG market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €31.02 Million ≈ $36.26 Million |
+2.49% |
| 2023-12-31 | €30.26 Million ≈ $35.38 Million |
-27.19% |
| 2022-12-31 | €41.57 Million ≈ $48.60 Million |
+2.10% |
| 2021-12-31 | €40.71 Million ≈ $47.60 Million |
+1077.27% |
| 2020-12-31 | €3.46 Million ≈ $4.04 Million |
-25.49% |
| 2019-12-31 | €4.64 Million ≈ $5.43 Million |
-34.02% |
| 2018-12-31 | €7.03 Million ≈ $8.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Apontis Pharma AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4748.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €8.50 Million | 27.40% |
| Other Components | €34.44 Million | 111.04% |
| Total Equity | €31.02 Million | 100.00% |
Apontis Pharma AG Competitors by Market Cap
The table below lists competitors of Apontis Pharma AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lakeshore Acquisition III Corp. Ordinary Shares
NASDAQ:LCCC
|
$91.63 Million |
|
Aniplus Inc
KQ:310200
|
$91.63 Million |
|
Rani Therapeutics Holdings Inc
NASDAQ:RANI
|
$91.70 Million |
|
Galleon Gold Corp
V:GGO
|
$91.71 Million |
|
Summit State Bank
NASDAQ:SSBI
|
$91.62 Million |
|
Manoj Vaibhav Gems 'N' Jewellers Limited
NSE:MVGJL
|
$91.62 Million |
|
Krystal Integrated Services Ltd
NSE:KRYSTAL
|
$91.60 Million |
|
Oneview Healthcare Plc
AU:ONE
|
$91.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apontis Pharma AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,263,184 to 31,016,754, a change of 753,570 (2.5%).
- Net income of 753,569 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €753.57K | +2.43% |
| Other Changes | €1.00 | +0.0% |
| Total Change | €- | 2.49% |
Book Value vs Market Value Analysis
This analysis compares Apontis Pharma AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.95x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.15x to 2.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.55 | €11.00 | x |
| 2020-12-31 | €0.41 | €11.00 | x |
| 2021-12-31 | €4.79 | €11.00 | x |
| 2022-12-31 | €4.89 | €11.00 | x |
| 2023-12-31 | €3.56 | €11.00 | x |
| 2024-12-31 | €3.72 | €11.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apontis Pharma AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.55%
- • Asset Turnover: 1.09x
- • Equity Multiplier: 1.43x
- Recent ROE (2.43%) is above the historical average (-19.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -51.57% | -5.98% | 1.31x | 6.59x | €-2.86 Million |
| 2020 | -34.21% | -3.01% | 1.32x | 8.59x | €-1.53 Million |
| 2021 | -1.83% | -1.46% | 0.95x | 1.33x | €-4.82 Million |
| 2022 | 6.47% | 4.82% | 0.93x | 1.44x | €-1.47 Million |
| 2023 | -37.35% | -30.58% | 0.64x | 1.90x | €-14.33 Million |
| 2024 | 2.43% | 1.55% | 1.09x | 1.43x | €-2.35 Million |
Industry Comparison
This section compares Apontis Pharma AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $860,644,378
- Average return on equity (ROE) among peers: -91.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apontis Pharma AG (APPH) | €31.62 Million | -51.57% | 0.39x | $91.63 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.51 Billion | 11.81% | 0.39x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $148.83 Million |
| Alkermes plc (8AK) | $1.07 Billion | 1.94% | 0.48x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $9.58 Million | -63.03% | 0.52x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $2.57 Million | 9.87% | 19.25x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $3.54 Million | -57.78% | 0.18x | $1.75 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more